

Top Tier NExT Applications

from Academia

Applicant PI	Center	Title	Cycle
Bresnick, Anne R.	Albert Einstein College of Medicine	Development of S100A4 inhibitors	01
Deshaias, Raymond	California Institute of Technology	Small Molecule Inhibitors of ATPase p97	01
Earp, H. Shelton	University of North Carolina-Chapel Hill	Developing Small Molecule Mer Inhibitor	01
Frangioni, John V.	Beth Israel Deaconess Medical Center	NIR Fluorophore for Image-Guided Surgery	01
Grandis, Jennifer R.	University of Pittsburgh	Inhibitors of STAT3 Activation	01
Hsieh, James J.	Washington University-St. Louis/MSKCC	Optimization of Lead Small Molecule Inhibitors of Taspase 1 for Cancer Therapeutics	01
Vogelstein, Bert	Johns Hopkins University	MTAP Isogenic Drug Screen	01
Altieri, Dario C.	University of Massachusetts Medical School	Clinical Development of Mitochondrial-Targeted Hsp90 Antagonists, Gamitrinibs	02
Dang, Chi	Johns Hopkins University School of Medicine	Development of FX11, a Lactate Dehydrogenase A (LDHA) Inhibitor, as an Anti-neoplastic Agent	02
Melnick, Ari	Joan & Sanford I Weill Medical College	Clinical Translation of a BCL-6 Inhibitor	02
Prochownik, Edward V.	Children's Hospital of Pittsburgh	Evaluation of Rationally-Designed Small Molecules Directed Against the c-Myc Oncoprotein	02
Roden, Richard B.	Johns Hopkins University	Production of an HPV16 L2E6E7 Vaccine with GPI-0100 Adjuvant for the Treatment of HPV-associated Disease	02
Frye, Stephen	University of North Carolina	Assay Development and Hit Discovery for IDH1-Based Approaches Targeting Glioblastoma	03
Alvarez, Ronald	The University of Alabama at Birmingham	A Novel and High Potency Combination Treatment Using Ad5-Delta24RGD and Chemotherapy for Human Ovarian Cancer	04
Doemling, Alexander	University of Pittsburgh	p53/MDM4/MDM2 Antagonists	04
Mazar, Andrew Paul	Northwestern University	huATN-658, a Humanized Monoclonal Antibody Targeting the Urokinase Receptor	04
Rathmell, Wendy Kimryn	The University of North Carolina	Ror2 as a Target for Renal Carcinoma	04
Kirsch, David	Duke University Medical Center	Using Molecular Imaging to Detect Microscopic Residual Cancer During Surgery	05
Miller, Jeffrey	University of Minnesota - Twin Cities	rhIL-15 to Exploit NK Cells in Cancer Therapy	05
Liu, Yang	University of Michigan	Development of Clinical Grade Echinomycin for Post-remission Therapy of AML	08
Rosenthal, Eben	The University of Alabama at Birmingham	Intraoperative Optical Imaging to Guide Surgical Resection of Cancer	08
Lieber, Michael	University of Southern California	Inhibitors of the Artemis Endonuclease for Cancer Chemotherapy	09
Heyer, Wolf-Dietrich	University of California Davis	Inhibitors of Recombinational DNA Repair	10

Fesik, Stephen	Vanderbilt University Medical Center	Discovery of Subnanomolar Inhibitors of Mcl-1	11
Fu, Haiyan	Emory University	Targeting Oncogenic Protein-protein Interactions for Therapeutic Discovery	11

from Private Sector - Biotechnology Companies

Applicant PI	Center	Title	Cycle
Leopold, Lance	Ascenta Therapeutics, Inc.	AT-406, a Pan, Oral IAP Inhibitor	01
Kovach, John S.	Lixte Biotechnology Holdings, Inc.	Novel Inhibitor of PP2A Potentiates Chemotherapy	02
Leigh, Bryan	Tracon Pharmaceuticals	Development of TRC105 as a Novel Antiangiogenic Monoclonal Antibody	02
Davis, Thomas	Celldex Therapeutics, Inc.	Clinical Development of CDX-1308 Vaccine Regimen	03
Graham, Martin	Tetralogic Pharmaceuticals	Predictive Biomarkers of SMAC-Mimetic (TL32711) Efficacy in Ovarian Cancer	04
Paradiso, Linda J.	America Stem Cell, Inc.	Accelerated Hematopoietic Recovery with ASC101	04
Roninson Porter, Igor	Senex Biotechnology, Inc.	Optimization and Testing of CDK3 Inhibitors	04
Frankel, Stanley	Micromet	Blinatumomab Clinical Development for B-lineage Malignancies	05
Hamdy, Ahmed	Pharmacyclics, Inc.	PCI-32765, Btk Inhibitor for B-cell Malignancies	05
Klein, Pamela	Intellikine, Inc.	INK128 a TORC1/2 Inhibitor in Solid Tumors and Hematologic Malignancies	06
Frye, John	Exelixis, Inc.	XL184 (Cabozantinib)	07
Miller, Langdon	Gilead (formerly Calistoga)	CAL-101 for Patients with Neoplastic Diseases	07
Hussein, Mohamad	Celgene Corporation	Pomalidomide in Rare Diseases with Unmet Medical Needs	08
Leigh, Bryan	Tracon Pharmaceuticals	Development of TRC102 as a Novel Inhibitor of Base Excision Repair	08
Wagner, Anthony	Amgen Incorporated	Ganitumab (AMG 479) CRADA	08
Leopold, Lance	Incyte Corporation	INCB024360, A Novel Orally-Administered IDO 1 Inhibitor for Cancer Treatment	09
Orton, Darren	StemSynergy Therapeutics, Inc.	Development of a Wnt Inhibitor	09
Wolchok, Jedd	Memorial Sloan-Kettering Cancer Center	Manufacturing of a VRP-TRP2 Vaccine for a Phase I Clinical Trial	10
Tabakoff, Boris	Lohocla Research Corporation	Cancer and Cancer Therapy Induced Neuropathic Pain: Treatment Prevention	11

from Private Sector – Pharmaceutical Companies

Applicant PI	Center	Title	Cycle
Marapaka, Praveen	MedImmune	HA 22 Randomized PIII-HCL	03
Huszar, Dennis	AstraZeneca	AZD1480 JAK1/2 Inhibitor	04

Fleming, Ronald	GlaxoSmithKline	GSK2118436 BRAF Inhibitor	05
Levin, Jeremy	GlaxoSmithKline	Oral MEK Inhibitor GSK1120212	06
Johnson, Lisa	Bristol-Myers Squibb	BMS-936558 Anti-PD-1 Antibody Treatment of Cancer	11
Pluda, James	Merck	Merck Agent MK-3475, an Anti-PD1 Monoclonal Antibody (mAb)	11
Watson, Patricia	Merck	HDM2; MK-8242 NExT Application	11

from Non-Profit Organizations

Applicant PI	Center	Title	Cycle
Reed, John C.	Sanford-Burnham Medical Research Institute	Chemical Activators of the PML Tumor Suppressor Pathway	01
Reed, John C.	Sanford-Burnham Medical Research Institute	Chemical Modulators of Autophagy	01
Kufe, Donald W.	Dana-Farber Cancer Institute	The Development of a Novel Anti-Cancer Agent Against the MUC1 Oncoprotein	02
Sadar, Marianne	British Columbia Cancer Agency	IND-Directed Preclinical Studies of EPI-001 for Prostate Cancer Treatment	03
Cravatt, Benjamin	The Scripps Research Institute	Development of Monoacylglycerol-Lipase Inhibitors for Cancer Therapy	06
Thottassery, Jaideep	Southern Research Institute	Preclinical Development of T-dCyd: A New Epigenetic Agent	07
Ronai, Ze'ev	Sanford-Burnham Medical Research Institute	Chemical Inducers of ATF2-mediated Apoptotic Activity in Melanoma	09

from Government

Applicant PI	Center	Title	Cycle
Waldmann, Thomas	National Cancer Institute, CCR	Anti-IL-15 Receptor Antibody Therapy of Celiac Disease Associated Lymphoma	03
Choyke, Peter	Center for Cancer Research, NCI, NIH	A Phase II Study of F-18 DCFBC, a Prostate Specific Membrane Antigen-Target	11